Ocular Therapeutix Statistics
Total Valuation
OCUL has a market cap or net worth of $1.60 billion. The enterprise value is $1.24 billion.
Important Dates
The next estimated earnings date is Friday, November 8, 2024, after market close.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
OCUL has 155.92 million shares outstanding. The number of shares has increased by 49.22% in one year.
| Shares Outstanding | 155.92M |
| Shares Change (YoY) | +49.22% |
| Shares Change (QoQ) | +25.60% |
| Owned by Insiders (%) | 2.20% |
| Owned by Institutions (%) | 69.92% |
| Float | 118.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 19.63 |
| Forward PS | 22.77 |
| PB Ratio | 4.28 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 20.22 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.64, with a Debt / Equity ratio of 0.20.
| Current Ratio | 16.64 |
| Quick Ratio | 16.35 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.72 |
Financial Efficiency
Return on equity (ROE) is -72.67% and return on invested capital (ROIC) is -27.49%.
| Return on Equity (ROE) | -72.67% |
| Return on Assets (ROA) | -22.37% |
| Return on Capital (ROIC) | -27.49% |
| Revenue Per Employee | $228,828 |
| Profits Per Employee | -$518,206 |
| Employee Count | 267 |
| Asset Turnover | 0.19 |
| Inventory Turnover | 36.37 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +215.03% in the last 52 weeks. The beta is 1.26, so OCUL's price volatility has been higher than the market average.
| Beta (5Y) | 1.26 |
| 52-Week Price Change | +215.03% |
| 50-Day Moving Average | 9.55 |
| 200-Day Moving Average | 7.76 |
| Relative Strength Index (RSI) | 49.18 |
| Average Volume (20 Days) | 1,293,016 |
Short Selling Information
The latest short interest is 13.26 million, so 8.51% of the outstanding shares have been sold short.
| Short Interest | 13.26M |
| Short Previous Month | 16.19M |
| Short % of Shares Out | 8.51% |
| Short % of Float | 11.15% |
| Short Ratio (days to cover) | 8.25 |
Income Statement
In the last 12 months, OCUL had revenue of $61.10 million and -$138.36 million in losses. Loss per share was -$1.25.
| Revenue | 61.10M |
| Gross Profit | -25.31M |
| Operating Income | -114.47M |
| Pretax Income | -138.36M |
| Net Income | -138.36M |
| EBITDA | -110.75M |
| EBIT | -114.47M |
| Loss Per Share | -$1.25 |
Full Income StatementBalance Sheet
The company has $459.69 million in cash and $74.89 million in debt, giving a net cash position of $384.80 million or $2.47 per share.
| Cash & Cash Equivalents | 459.69M |
| Total Debt | 74.89M |
| Net Cash | 384.80M |
| Net Cash Per Share | $2.47 |
| Equity (Book Value) | 377.70M |
| Book Value Per Share | 2.43 |
| Working Capital | 468.61M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$88.88 million and capital expenditures -$1.72 million, giving a free cash flow of -$90.59 million.
| Operating Cash Flow | -88.88M |
| Capital Expenditures | -1.72M |
| Free Cash Flow | -90.59M |
| FCF Per Share | -$0.58 |
Full Cash Flow StatementMargins
Gross margin is -41.42%, with operating and profit margins of -187.36% and -226.46%.
| Gross Margin | -41.42% |
| Operating Margin | -187.36% |
| Pretax Margin | -226.46% |
| Profit Margin | -226.46% |
| EBITDA Margin | -181.26% |
| EBIT Margin | -187.36% |
| FCF Margin | -148.27% |
Dividends & Yields
OCUL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -49.22% |
| Shareholder Yield | -49.22% |
| Earnings Yield | -8.54% |
| FCF Yield | -5.59% |
Analyst Forecast
The average price target for OCUL is $16.38, which is 59.49% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $16.38 |
| Price Target Difference | 59.49% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 41.32% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
OCUL has an Altman Z-Score of 0.85 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.85 |
| Piotroski F-Score | 2 |